Mild X-linked Alport syndrome due to the COL4A5 G624D variant originating in the Middle Ages is predominant in Central/East Europe and causes kidney failure in midlife

• Published in: Kidney international Vol. 99; no. 6; p. 1451
• Main Authors: Żurowska, Aleksandra M, Bielska, Olga, Daca-Roszak, Patrycja, Jankowski, Maciej, Szczepańska, Maria, Roszkowska-Bjanid, Dagmara, Kuźma-Mroczkowska, Elżbieta, Pańczyk-Tomaszewska, Małgorzata, Moczulska, Anna, Drożdż, Dorota, Hadjipanagi, Despina, Deltas, Constantinos, Ostalska-Nowicka, Danuta, Rabiega, Alina, Taraszkiewicz, Janina, Taranta-Janusz, Katarzyna, Wieczorkiewicz-Plaza, Anna, Jobs, Katarzyna, Mews, Judyta, Musiał, Kinga, Jakubowska, Anna, Nosek, Hanna, Jander, Anna E, Koutsofti, Constantina, Stanisławska-Sachadyn, Anna, Kuleszo, Dominka, Ziętkiewicz, Ewa, Lipska-Ziętkiewicz, Beata S
• Format: Journal Article
• Language: English
• Published: United States 01-06-2021
• Subjects: Adult; Child; Collagen Type IV - genetics; DNA Mutational Analysis; Europe; Founder Effect; Humans; Male; Middle Aged; Nephritis, Hereditary - genetics; Renal Insufficiency; Europe; genetic; prediction; COL4A5; chronic kidney disease; Alport syndrome
• ISSN: 1523-1755
• DOI: 10.1016/j.kint.2020.10.040

A study of 269 children enrolled into a National Registry for children with persistent glomerular hematuria identified 131 individuals with genetically confirmed X-linked Alport Syndrome. A single variant c.1871G>A p.Gly624Asp (G624D) in COL4A5 was predominant and accounted for 39% of X-linked Alport Syndrome in unrelated Polish families (44 of 113). To evaluate its origins, the genetic variation in a 2.79 Mb segment encompassing the COL4A5 locus on chromosome X was assessed. All G624D alleles were found on the same rare haplotype background, indicating a founder effect dating back to the 12-13th century. The phenotypic data of 131 children with X-linked Alport Syndrome and their 195 affected adult relatives revealed that the G624D variant was associated with a significantly milder clinical course in comparison to other pathogenic COL4A5 variants. Furthermore the clinical course of this genetically uniform cohort was milder than that observed in individuals with other COL4A5 missense mutations. In spite of the benign clinical manifestation throughout childhood and early adulthood, the G624D variant confers significant risk for both kidney failure and deafness in males, albeit 20-30 years later than that observed in individuals with other COL4A5 pathogenic variants (50% cumulative risk of starting dialysis at 54 years (95% confidence interval: 50-62) v. 26 years (95% confidence interval: 22-30)). Thus, males with G624D are candidates for existing and emerging therapies for Alport Syndrome.